VentiRx Cancer Drug Passes Early Trial

Xconomy San Diego — 

VentiRx Pharmaceuticals, the San Diego and Seattle-based drug developer, said today its experimental treatment for cancer passed its initial clinical trial in 33 patients. The drug, VTX-2337, was found to be safe and well-tolerated in the study and showed increasing signs of activity as doses escalated, the company said. The drug is designed to stimulate the innate immune system to fight tumors, in tandem with standard cancer treatments, VentiRx said. The company plans to take the next step, with a Phase Ia/2b trial, “in the near future,” according to a statement.